OncoCyte is a diagnostics & research business based in the US. OncoCyte shares (OCX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $3.11 – an increase of 0.32% over the previous week. OncoCyte employs 43 staff and has a trailing 12-month revenue of around $1 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $3.11 |
|---|---|
| 52-week range | $2.08 - $4.34 |
| 50-day moving average | $3.06 |
| 200-day moving average | $2.98 |
| Wall St. target price | $4.13 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-4.28 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $3.12 from 2024-10-15
| 1 week (2024-10-11) | 2.30% |
|---|---|
| 1 month (2024-09-18) | 5.76% |
| 3 months (2024-07-18) | 3.12 |
| 6 months (2024-04-18) | 21.88% |
| 1 year (2023-10-18) | 1.11% |
|---|---|
| 2 years (2022-10-18) | 310.53% |
| 3 years (2021-10-18) | 3.3 |
| 5 years (2019-10-18) | 84.62% |
| Revenue TTM | $1 million |
|---|---|
| Gross profit TTM | $188,000 |
| Return on assets TTM | -16.67% |
| Return on equity TTM | -101.76% |
| Profit margin | 0% |
| Book value | $1.70 |
| Market Capitalization | $52.5 million |
TTM: trailing 12 months
We're not expecting OncoCyte to pay a dividend over the next 12 months.
OncoCyte's shares were split on a 1:20 basis on 24 July 2023. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your OncoCyte shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for OncoCyte shares which in turn could have impacted OncoCyte's share price.
Over the last 12 months, OncoCyte's shares have ranged in value from as little as $2.08 up to $4.34. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while OncoCyte's is 1.006. This would suggest that OncoCyte's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test. It also provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. (Bio-Rad) to collaborate in the development and the commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California. .
Fundamental analysis of stocks can help you become a better investor and find the true value of stocks and other assets.
These are the stocks to buy when you don’t have much to spend.
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
These are the best day trading apps, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Titan invest is a members-only automated platform best for hands-off investors looking to build wealth.
A beginner-friendly investing platform with fractional shares and no commissions on stocks and ETFs.
What you need to know about investing in the leading indicator for the overall US stock market.
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.
Read our beginner’s guide to trading options in the US.